I-Androstenedione I-Steroid Evinjiwe

I-Androstenedione (Andro) iyisisindo sokwakha imisipha ukuthi ikhaya lebhola likaMark uMark McGwire lenze udumo. Kodwa kusukela kuleso siqephu, siye sahlukaniswa njenge- anabolic steroid futhi kanjalo, akuvumelekile ukusebenzisa ngaphandle kwesizathu sempilo esivumelekile.

Futhi ebizwa ngokuthi: 4-androstenedione noma i-4-androstene-3, 17-dione

Yini Androstenedione Eyenza?

I-Androstenedione yenziwa nge-hormone eyenziwa ngokwemvelo.

Emzimbeni wakho, i-androstenedione iyi-prohormone ekhiqizwa yizigulane ezinama-adrenal, testes, nama-ovaries. Umzimba ulungisa i-androstenedione ku- testosterone , i-hormone eyinhloko, kanye nase-estrogens estrone ne-estradiol. Uma usebenzisa i-andro njenge-supplement yayingokomthetho, isetshenziselwa ukwethemba ukuthuthukisa amazinga e-testosterone emzimbeni. Ngaphandle kokunikeza kokubili amadoda nabesifazane izici zesilisa, i-testosterone inomphumela we-anabolic, ukwandisa usayizi wamascle namandla.

I-androstenedione yokwelashwa ingasetshenziselwa ukwandisa amazinga e-testosterone e-plasma. Izifundo kaningi azitholanga izithako ze-androstenedione ukuze ziphumelele ekwandiseni amazinga e-testosterone. Ucwaningo oluthile lwabonisa ukuthi umphumela wenetha wawuwukuba kuthuthukiswe izinga le-estrogen kunalokho, futhi awunayo impumelelo ye-anabolic emisipha kumadoda amasha. Isetshenziselwa ukwesekwa, njengoba kubonakala nokuba nemiphumela emibi ekunciphiseni i-HDL ye-cholesterol, engakhuphula izingozi ze-heart coronary kubantu.

I-Androstenedione Sebenzisa ku-Sports

Sekuyiminyaka i-Major League Baseball ingavimanga i-andro naphezu kobufakazi bokuthi ukusetshenziswa kwayo kungaba yingozi kulabo abayithatha ngaphandle kwesizathu sempilo esivumelekile. Kwakukade kuvinjelwe yi-Anti-Doping Agency, iKomidi Lomhlaba Wonke Wama-Olimpiki, i-NCAA, i-NFL kanye nohambo lwamadoda kanye nabesifazane.

NgoJanuwari ka-2005, uMthetho Wokulawulwa Kwama-Anabolic Steroid wachitshiyelwa nge-Controlled Substance Act eyanezela ama-anabolic steroids kanye nama-prohormones ohlwini lwezinto ezilawulwayo. Lokhu kwenza izinto zibe yibugebengu obuphethwe nguhulumeni. Ngo-2004, i-United States Food and Drug Administration (FDA) yavinjelwa ukuthengiswa kuka-Andro, ngenxa yobufakazi obusekela ukunyuka kwengozi yezempilo lapho usebenzisa le nto.

I-FDA Alert Import Alert 54-11, yango-9/15/2015, inikeza iziqondiso ezifundeni ukuthi noma yikuphi ukudla okunomsoco we-androstenedione, i-4-androstenedione noma i-4-androstene-3, i-17-dione ingagcinwa ngaphandle kokuhlolwa ngokomzimba. Ukufakwa kuhlu nje kungenxa yokuvimbela ukungenisa kwayo e-United States.

Okuqhamuka uma udla imishanguzo

Ucwaningo lwaluxutshwe ngokuthi ngabe ama-andro asetshenziselwa yini ukusebenzela amazinga e-testosterone, kodwa kuboniswe ukuthi banezimo ezimbi futhi bakhulisa izingozi zempilo.

Ikwazi ukuxhumana nabantu abambalwa begazi abanjengoCoumadin nama-salicylates. Kungabuye futhi ixhumane nezidakamizwa zesifo sikashukela ezifana ne-sulfonylurea ne-insulin, ukunciphisa ukuhlushwa kwe-glucose yegazi. Kungabangela ama-acne aqinile noma i-edema uma kuthathwe i-corticosteroids.

I-US FDA White Paper ngemiphumela yezempilo ka-Androstenedione ngo-2005 yakhulume imiphumela emibi ababesabayo ukuthi izokwenzeka kubantwana nasebancane abathatha i-andro isikhathi eside.

Lokhu kwakuhlanganisa abesifazane besifazane kanye nempilo yamantombazane. Ukukhulelwa ngaphambi kwesikhathi kungaholela ekufinyeleleni kwesifushane.

Ukwanda kwe-testosterone kumadoda amadala kungaholela engozini yokwanda komdlavuza we-prostate, kanye nokukhula komdlavuza wesibindi kanye nomdlavuza webele emabesilisa nabesifazane.

Imithombo:

Isikhungo Sikazwelonke se-Biotechnology Information. I-PubChem Database Compound; CID = 6128, https://pubchem.ncbi.nlm.nih.gov/compound/6128

I-US FDA; I-FDA White Paper Imiphumela Yezempilo Ye-Androstenedione. Ngo-Mashi 11, 2004

Thomson.Micromedex. Ulwazi Lwadakamizwa Lwezempilo Lwezempilo. 25th ed. Umqulu 1. Plus Updates. Okuqukethwe Okubuyekezwe yi-United States Pharmacopeial Convention, Inc. Greenwood Village, CO 2005., k. 142.